Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRBN-SOS1 degrader refers to a class of bifunctional small molecules, specifically a program developed by Biotheryx using their PRODEGY platform, designed to induce the proteasomal degradation of SOS1 (Son of Sevenless homolog 1). By recruiting the Cereblon (CRBN) E3 ubiquitin ligase to SOS1, these degraders deplete the SOS1 protein, which serves as a critical guanine nucleotide exchange factor (GEF) for RAS proteins. This degradation leads to a reduction in active, GTP-loaded KRAS, HRAS, and MRAS, subsequently inhibiting downstream MAPK pathway signaling (measured by pERK and pS6 levels). Preclinical studies have demonstrated potent anti-proliferative activity across a wide range of KRAS mutations (including G12C, G12D, G12V, and G13D) and have shown strong synergy when combined with KRAS inhibitors, MEK inhibitors, or EGFR inhibitors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CRBN-SOS1 degrader.